Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Altamira Therapeutics Ltd (CYTO)

Altamira Therapeutics Ltd (CYTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,439
  • Shares Outstanding, K 3,401
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,310 K
  • EBIT $ 0 M
  • EBITDA $ -6 M
  • 60-Month Beta 1.81
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.16
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on 03/14/19
  • Next Earnings Date 09/24/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4000 +5.75%
on 11/19/24
0.6200 -31.77%
on 11/14/24
-0.1421 (-25.15%)
since 10/22/24
3-Month
0.4000 +5.75%
on 11/19/24
1.0500 -59.71%
on 08/23/24
-0.5614 (-57.03%)
since 08/22/24
52-Week
0.4000 +5.75%
on 11/19/24
17.2000 -97.54%
on 11/30/23
-5.5570 (-92.93%)
since 11/22/23

Most Recent Stories

More News
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:RENB),(NASDAQ:CYTO),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END

ONCY : 0.9541 (-2.64%)
ONC.TO : 1.33 (-2.92%)
RENB : 0.5190 (+3.63%)
CYTO : 0.4230 (-3.31%)
PFE : 25.65 (+2.07%)
ABBV : 176.95 (+3.04%)
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032

ONCY : 0.9541 (-2.64%)
ONC.TO : 1.33 (-2.92%)
RENB : 0.5190 (+3.63%)
CYTO : 0.4230 (-3.31%)
PFE : 25.65 (+2.07%)
ABBV : 176.95 (+3.04%)
Altamira Therapeutics’ (NASDAQ: CYTO) Clinical Data on Bentrio Showing Strong Nasal Residence and Rheological Properties

Altamira Therapeutics, Ltd. (NASDAQ: CYTO) is engaged within the research and development of RNA-based therapies for extrahepatic targets and unmet

CYTO : 0.4230 (-3.31%)
Altamira Therapeutics’ CEO Interviewed by Proactive Investors to Discuss its Pipeline of RNA Therapeutics and Ongoing Strategic Transformation

HAMILTON, BERMUDA , Aug. 03, 2022 (GLOBE NEWSWIRE) -- Altamira’s patented RNA delivery technology platform is addressing strong need for reaching target...

CYTO : 0.4230 (-3.31%)
Altamira Therapeutics Completes Interim Sample Size Analysis of COVAMID Trial with Bentrio in Acute COVID-19

HAMILTON, BERMUDA , Aug. 01, 2022 (GLOBE NEWSWIRE) -- Enrollment to be continued to 160 subjects, adding 24 to ensure adequate statistical powerTop-line...

CYTO : 0.4230 (-3.31%)
Altamira Therapeutics’ Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed Journal

•Independent peer-reviewed study confirms high potential for OligoPhoreTM delivery platform in RNA-based treatments for osteoarthritis •Knock down of...

CYTO : 0.4230 (-3.31%)
Altamira Therapeutics to Develop Novel Generation of Rheumatoid Arthritis Therapeutics Based on its Proprietary OligoPhore Delivery Platform and siRNA Targeting Key Inflammation Checkpoint

•Company’s novel drug development program AM-411 builds on positive animal data •Treatments for rheumatoid arthritis represent the second largest...

CYTO : 0.4230 (-3.31%)
Altamira Therapeutic's SemaPhore Platform Shown Particularly Effective in Intracellular mRNA Delivery for Cancer Therapy

Peer-reviewed study highlights high potential for cell-penetrating peptides in mRNA-based cancer treatmentsDemonstrates effective uptake and...

CYTO : 0.4230 (-3.31%)
Altamira Therapeutic’s RNA Delivery Platform Shown to be an Effective Treatment for Abdominal Aortic Aneurysm as Published in Peer-Reviewed Journal

HAMILTON, BERMUDA / ACCESSWIRE / July 12, 2022 / Altamira Therapeutics ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs,...

CYTO : 0.4230 (-3.31%)
Altamira Therapeutics Secures Marketing & Distribution Agreements To Expand Sales Channels of Bentrio into Egypt and Pakistan

Two Additional Distributors Further Expand Company's Growing Global Footprint To Offer Its Bentrio Nasal Spray for Protection Against Airborne Allergens and Viruses

CYTO : 0.4230 (-3.31%)

Business Summary

Altamira Therapeutics Ltd. is dedicated to developing therapeutics which addresses unmet medical needs. The Company is currently active in the development of RNA therapeutics for extrahepatic therapeutic targets, nasal sprays for protection against airborne viruses and allergens or the treatment of vertigo...

See More

Key Turning Points

3rd Resistance Point 0.5087
2nd Resistance Point 0.4884
1st Resistance Point 0.4557
Last Price 0.4230
1st Support Level 0.4027
2nd Support Level 0.3824
3rd Support Level 0.3497

See More

52-Week High 17.2000
Fibonacci 61.8% 10.7824
Fibonacci 50% 8.8000
Fibonacci 38.2% 6.8176
Last Price 0.4230
52-Week Low 0.4000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar